Timing immunotherapy with body rhythms for advanced melanoma
Part of Cancer, Skin clinical trials.
This study tests whether giving immunotherapy (medicines that help your immune system fight cancer) at specific times of day—aligned with your body's natural rhythms—works better for advanced melanoma. Researchers will randomly assign you to receive treatment either on a timed schedule or a standard schedule.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Melanoma that cannot be surgically removed (stage III or IV) confirmed by biopsy
- Cancer that can be measured on imaging or physically examined
- Age 18 or older
- Good enough overall health to receive immunotherapy (ECOG score 0–2: able to do daily activities with some or minimal limitations)
- No prior systemic chemotherapy or immunotherapy (except certain prior treatments if stopped >6 months ago)
- Not pregnant, not breastfeeding, and willing to use birth control during treatment and for 5 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
This trial tests a treatment that activates the body’s immune cells (natural killer cells) using a target called CD160. It may help people with advanced melanoma, especially when the cancer can’t be removed with surgery.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.